New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

BioCell Technology's new I-Sabi research white paper - Booth #807

BioCell Technology has issued a white paper on its patent-pending i-Sabi dietary ingredient, which is made from the plant rhizome of Wasabia japonica, more commonly known as wasabi. Wasabi contains a wide spectrum of bioactivities, including antioxidant, liver-protective, anti-inflammatory, anti-carcinogenic, immunomodulatory, neuritogenic and anti-bacterial properties. Wasabia japonica is a member of the Brassicacea or cruciferous vegetable family. Chemical analysis has shown the presence of a variety of bioactive compounds, such as isothiocyanates, vitamins, essential oils and minerals, but it is 6-HITC (6-methylsulfinylhexyl isothiocyanate) that has been shown to harbor the wide range of potential health benefits. I-Sabi developed by BioCell contains approximately 15,000ppm of 6-HITC, higher than other commercially available wasabi products, and is sold as a freeze-dried powder, which can be formulated into capsules, tablets and soft gels, either as a novel product or as an additional constituent.

Visit BioCell at Booth #807.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.